The CSL Board is responsible for oversight of the management of the Company and providing strategic direction.

The Executive Management is responsible for the day to day running of CSL.

CSL Board Members

_{John Shine Chairman}	_{Brian McNamee Chief Executive Officer and Managing Director}	_{Peter Turner}

_{John Akehurst}	_{David Anstice}	_{Bruce Brook}

_{Christine O'Reilly}	_{Ian Renard}	_{Maurice Renshaw}

John Shine, AO

_{BSc (Hon), PhD, DSc, FAA - (Age 65)}

^{Pharmaceutical Industry and Medicine (Resident in NSW)}
Chairman
Professor Shine was appointed to the CSL Board in June 2006 and became Chairman in 2011. He is Executive Director of the Garvan Institute of Medical Research and a Board Member of the Garvan Research Foundation. He is Professor of Molecular Biology and Professor of Medicine at the University of NSW, and a Director of many scientific research and medical bodies throughout Australia. Professor Shine was formerly Chairman of the National Health and Medical Research Council (NHMRC) and a Member of the Prime Minister’s Science, Engineering and Innovation Council (PMSEIC). In November 2010, he was awarded the 2010 Prime Minister's Prize for Science.

^{Professor Shine is a member of the Innovation and Development Committee.}

Brian A McNamee, AO

_{MBBS, FAICD, FTSE - (Age 54)}

^{International Pharmaceutical Industry, Medicine (Resident in Victoria)}Chief Executive Officer and Managing Director
Dr McNamee was appointed to the CSL Board in July 1990 and is the Chief Executive Officer and Managing Director. Dr McNamee is a former Director of the Peter MacCallum Cancer Foundation Ltd. Dr McNamee completed Bachelor of Medicine and Bachelor of Surgery Degrees at the University of Melbourne.

^{Dr McNamee is a member of the Innovation and Development Committee.}

Peter J Turner

_{BSc, MBA, MAICD – (Age 62)}
^{International Pharmaceutical Industry (Resident in Pennsylvania, USA)}Executive Director
Mr Turner was appointed to the CSL Board in December 2009. He has more than 40 years experience in the biopharmaceutical industry. His expertise includes plasma fractionation, research and development, production, engineering and management. Mr Turner contributed to the successful acquisition of Aventis Behring to form CSL Behring in 2004 served as President of CSL Behring from that time until June 2011. He was also Chief Operating Officer, CSL Group until June 2011.

John H Akehurst

_{MA (Oxon), FIMechE - (Age 62)}
^{Engineering and Management (Resident in Western Australia)}Mr Akehurst was appointed to the CSL Board in April 2004. He had 30 years’ executive experience in the international hydrocarbon industry, including seven years as Managing Director and CEO of Woodside Petroleum Ltd. Mr Akehurst is a member of the Board of the Reserve Bank of Australia and is also a Director of Origin Energy Limited and of Securency International Pty Ltd. He was formerly Chairman of Alinta Limited and of Coogee Resources Limited and is a former Director of Oil Search Limited. Mr Akehurst is Chairman of the National Centre for Asbestos Related Diseases and the Fortitude Foundation and a Director of the University of Western Australia’s Business School.

^{Mr Akehurst is a member of the Human Resources and Remuneration Committee.}

David W Anstice

_{BEc - (Age 63)}

^{International Pharmaceutical Industry (Resident in Pennsylvania, USA)}

Mr Anstice was appointed to the CSL Board in September 2008. Mr Anstice was a long-time member of the Board of Directors and Executive Committee of the US Biotechnology Industry Organisation, and has over 40 years’ experience in the global pharmaceutical industry. Until August 2008, Mr Anstice was for many years a senior executive of Merck & Co. Inc. serving at various times as President of Merck Human Health for US/Canada/Latin America, Europe, Japan and Asia as Executive Vice President. He is a Director of Alkermes, Inc., in Boston, Massachusetts, and a Director of the United States Studies Centre at the University of Sydney.

^{Mr Anstice is a member of the Human Resources and Remuneration Committee and the Innovation and Development Committee.}

Bruce R Brook

_{BCom, BAcc, FCA, MAICD - (Age 56)}
^{Finance and Management (Resident in Victoria)}Mr Brook was appointed to the CSL Board in August 2011. He is currently Chairman of Programmed Maintenance Services Limited and a Director of Boart Longyear Limited. Mr Brook has previously been Chairman of Energy Developments Limited and a Director of Lihir Gold Limited and Consolidated Minerals Limited. During his executive career he was Chief Financial Officer of WMC Resources Limited and prior to that the Deputy Chief Financial Officer of the ANZ Banking Group.

Christine E O’Reilly

_{BBus (Age 50)}
^{Finance and Infrastructure (Resident in Victoria)}Ms O’Reilly was appointed to the CSL Board in February 2011. She is currently Co-Head of Unlisted Infrastructure Investments at Colonial First State Global Asset Management, a position that she has held since July 2007. In this capacity, Ms O’Reilly is a Director of the Anglian Water Group (UK) and Electricity North West (UK). Prior to her position with Colonial First State Global Asset Management, Ms O’Reilly was the Chief Executive Officer of the GasNet Australia Group from October 2001 until December 2006. She is a Director of Care Australia.

^{Ms O’Reilly is a member of the Audit and Risk Management Committee and the Human Resources Remuneration Committee.}

Ian A Renard

_{BA, LLM, LLD (Hon), FAICD - (Age 65)}

^{Law (Resident in Victoria)}
Mr Renard was appointed to the CSL Board in August 1998. For many years he practised in company and commercial law. Mr Renard is a Director of Hillview Quarries Pty Ltd, SP Australia Networks (Distribution) Ltd and SP Australia Networks (Transmission) Ltd. He is the Chairman of the University of Melbourne Archives Advisory Board and a Trustee of the R E Ross Trust.

^{Mr Renard is Chairman of the Audit and Risk Management Committee.}

Maurice A Renshaw

_{B.Pharm. - (Age 64)}

^{International Pharmaceutical Industry (Resident in NSW)}Mr Renshaw was appointed to the CSL Board in July 2004. Formerly, he was Vice President of Pfizer Inc, USA, Executive Vice President, Pfizer Global Consumer Group and President of Pfizer’s Global Consumer Healthcare Division. Prior to his positions in Pfizer, Mr Renshaw was Vice President of Warner Lambert Co. and President of Parke-Davis USA. He has had more than 30 years’ experience in the international pharmaceutical industry.

^{Mr Renshaw is Chairman of the Innovation and Development Committee.}

Edward H Bailey

_{LLB, B.Com, FCIS - (Age 45)}

Company Secretary

Privacy | Terms of Use | Employees | Webmaster